AR094634A1 - Formulación de cápsulas de ácido 5-aminosalicílico - Google Patents

Formulación de cápsulas de ácido 5-aminosalicílico

Info

Publication number
AR094634A1
AR094634A1 ARP130104307A ARP130104307A AR094634A1 AR 094634 A1 AR094634 A1 AR 094634A1 AR P130104307 A ARP130104307 A AR P130104307A AR P130104307 A ARP130104307 A AR P130104307A AR 094634 A1 AR094634 A1 AR 094634A1
Authority
AR
Argentina
Prior art keywords
aminosalyclic
formulation
dosage form
tablets
acid capsules
Prior art date
Application number
ARP130104307A
Other languages
English (en)
Inventor
Boyd Emma
Caldwell Deborah
Coulter Catherine
Loughlin Ryan
Mcullagh Stephen
Original Assignee
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR094634(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Chilcott Co Llc filed Critical Warner Chilcott Co Llc
Publication of AR094634A1 publication Critical patent/AR094634A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulga una forma de dosificación que comprende una cápsula que contiene una o más comprimidos de ácido 5-aminosalicílico o una sal de este como un ingrediente activo, donde cada uno del uno o más comprimidos están recubiertos entéricamente. Reivindicación 2: Un kit que comprende: una forma de dosificación de acuerdo con la reivindicación 1; y una cantidad predeterminada de desecante. Reivindicación 3: Un método para tratar una afección inflamatoria del tracto gastrointestinal que comprende administrar Luna forma de dosificación de acuerdo con la reivindicación 1 a un paciente que necesita el tratamiento.
ARP130104307A 2012-11-21 2013-11-21 Formulación de cápsulas de ácido 5-aminosalicílico AR094634A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/683,080 US20140141075A1 (en) 2012-11-21 2012-11-21 5-aminosalicylic acid capsule formulation

Publications (1)

Publication Number Publication Date
AR094634A1 true AR094634A1 (es) 2015-08-19

Family

ID=50588745

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104307A AR094634A1 (es) 2012-11-21 2013-11-21 Formulación de cápsulas de ácido 5-aminosalicílico

Country Status (10)

Country Link
US (3) US20140141075A1 (es)
EP (1) EP2922532B1 (es)
CN (1) CN105209023A (es)
AR (1) AR094634A1 (es)
AU (1) AU2013356926B2 (es)
CA (1) CA2891638A1 (es)
IL (1) IL238790B (es)
MX (1) MX361275B (es)
SG (1) SG11201504012XA (es)
WO (1) WO2014091308A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210236519A1 (en) * 2020-01-30 2021-08-05 Atoz Pharmaceuticals Pvt Ltd Controlled release dosage forms of 5-aminosalicylic acid and process thereof
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
GEP19971086B (en) 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
CA2205553C (en) 1994-12-16 2009-04-07 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP5068401B2 (ja) * 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
JP3716901B2 (ja) 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US20030096001A1 (en) 2000-06-06 2003-05-22 Cherukuri S. Rao Encapsulation products and method of controlled release of fluoxetine or mesalamine
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
JP2004507487A (ja) 2000-08-29 2004-03-11 メファ・アクチェンゲゼルシャフト 腸疾患治療薬
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
MXPA04004747A (es) * 2001-11-23 2004-08-02 Procter & Gamble Forma de dosificacion farmaceutica con multiples recubrimientos.
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
ATE482694T1 (de) 2002-07-05 2010-10-15 Temrel Ltd Zusammensetzung zur kontrollierten wirkstoffabgabe
EP1462098B1 (en) * 2003-03-03 2007-07-04 SPRL Franpharma Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
CA2551183C (en) 2003-12-23 2013-05-28 Temrel Limited Process for producing pellets for pharmaceutical compositions
EP1784166B1 (en) * 2004-09-01 2009-03-04 The Procter and Gamble Company Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar
US20080020041A1 (en) 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US20090068263A1 (en) 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
US20090036414A1 (en) 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
SI2230932T1 (sl) 2008-01-10 2017-07-31 Evonik Roehm Gmbh Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu
WO2010040113A1 (en) 2008-10-03 2010-04-08 Salix Pharmaceuticals, Ltd. Compositions and methods for the treatment of bowel diseases with granulated mesalamine
AU2009333300A1 (en) * 2008-12-17 2011-08-11 Altheus Therapeutics, Inc. Oral formulations
WO2010099508A1 (en) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010105673A1 (en) 2009-03-18 2010-09-23 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
IT1395143B1 (it) 2009-08-06 2012-09-05 Sofar Spa Composizioni granulari a rilascio controllato di mesalazina e processo per il loro ottenimento.
WO2011045775A1 (en) 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
CN102869349A (zh) 2010-03-09 2013-01-09 阿尔科米斯制药爱尔兰有限公司 耐酒精的肠溶药物组合物
EP2425826A1 (en) 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
EP2822542A1 (en) * 2012-03-07 2015-01-14 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
EP2659881B1 (en) * 2012-04-30 2017-11-29 Tillotts Pharma Ag A delayed release drug formulation
WO2013176763A1 (en) 2012-05-19 2013-11-28 Salix Pharmaceuticals, Ltd Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate

Also Published As

Publication number Publication date
EP2922532B1 (en) 2019-03-06
US10265273B2 (en) 2019-04-23
IL238790A0 (en) 2015-06-30
WO2014091308A1 (en) 2014-06-19
AU2013356926B2 (en) 2018-07-05
US20140370083A1 (en) 2014-12-18
US20140141075A1 (en) 2014-05-22
IL238790B (en) 2019-12-31
US20190201348A1 (en) 2019-07-04
MX2015006356A (es) 2016-03-16
EP2922532A1 (en) 2015-09-30
SG11201504012XA (en) 2015-06-29
AU2013356926A1 (en) 2015-06-11
CA2891638A1 (en) 2014-06-19
CN105209023A (zh) 2015-12-30
US10688057B2 (en) 2020-06-23
MX361275B (es) 2018-12-03

Similar Documents

Publication Publication Date Title
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
AR094269A1 (es) Droga de direccionamiento a gpc3 para administrar a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
MX2019005300A (es) Polimeros enlazados al proton para administracion oral.
AR086395A1 (es) Envase para el tratamiento de patologias
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX345504B (es) Composiciones de vesicula.
PH12016501059A1 (en) A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
BR112019007539A2 (pt) formulações para liberação entérica de agentes terapêuticos
AR094634A1 (es) Formulación de cápsulas de ácido 5-aminosalicílico
EA201590847A1 (ru) Новые ингибиторы rock
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
JP2012041314A5 (es)
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
EA201590732A1 (ru) Диспергируемая таблетка
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
RU2012115039A (ru) Способ лечения хронического эндометрита
IN2013MU02586A (es)
IN2013MU02585A (es)
IN2013MU02587A (es)
EA201100827A1 (ru) Противотуберкулезное лекарственное средство
WO2013035053A3 (en) Novel conjugation-facilitated transport of drugs across blood brain barrier

Legal Events

Date Code Title Description
FB Suspension of granting procedure